Orris

Multiple sclerosis

Reading File
Finding Sources
Searching PubMed

"multiple sclerosis" AND "disease-modifying therapy"

Multiple sclerosis (MS) is a broad topic. Here's a map of what it covers, then I'll ask which part you want in depth.

Topic Breakdown

  1. Overview & Epidemiology - definition, prevalence, risk factors (genetic, EBV, vitamin D, smoking)
  2. Pathophysiology - autoimmune demyelination, plaque formation, axonal loss, role of T/B cells
  3. Clinical Course & Classification - relapsing-remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS), clinically isolated syndrome (CIS)
  4. Clinical Features - optic neuritis, sensory symptoms, Lhermitte's sign, internuclear ophthalmoplegia, bladder/bowel dysfunction, fatigue, cognitive changes
  5. Diagnosis - McDonald criteria, MRI findings (dissemination in space/time), CSF oligoclonal bands, differential diagnosis (NMOSD, MOGAD, mimics)
  6. Acute Relapse Management - IV corticosteroids, plasma exchange for refractory attacks
  7. Disease-Modifying Therapies (DMTs) - injectables (interferons, glatiramer), orals (fingolimod, dimethyl fumarate, teriflunomide, siponimod), infusions/monoclonals (natalizumab, ocrelizumab, alemtuzumab, cladribine), high-efficacy vs escalation strategies
  8. Symptomatic & Rehabilitative Management - spasticity, fatigue, pain, bladder issues, physical therapy
  9. Prognosis & Special Populations - pregnancy, pediatric MS, treatment discontinuation in stable disease

Brief Overview

Multiple sclerosis is a chronic, immune-mediated demyelinating disease of the central nervous system in which T- and B-cell-driven inflammation attacks myelin and axons, producing plaques disseminated in space and time within the brain, spinal cord, and optic nerves. It typically presents in young adults (20s-40s), more often women, with relapsing-remitting neurologic deficits (optic neuritis, limb weakness or numbness, diplopia, ataxia) that over years can transition to a progressive phase (SPMS) or, in about 10-15% of patients, begin as primary progressive disease (PPMS) from onset. Diagnosis relies on the McDonald criteria, combining clinical episodes with MRI evidence of lesions disseminated in space and time, supported by CSF oligoclonal bands, after excluding mimics like neuromyelitis optica spectrum disorder (NMOSD) and MOG-antibody disease (MOGAD).
Management has two arms: treating acute relapses (high-dose IV corticosteroids, plasma exchange if refractory) and long-term disease-modifying therapy to reduce relapse rate and slow disability accumulation, ranging from moderate-efficacy injectables/orals to high-efficacy monoclonal antibodies (natalizumab, ocrelizumab, ofatumumab) used either as first-line ("high-efficacy first") or after escalation. Recent systematic reviews (2024-2025) have examined network meta-analyses of DMTs in progressive MS and the safety of discontinuing DMTs in older, stable patients - both areas of active practice change (PMID: 38529035, PMID: 40614415).
Which of these would you like to go deeper on?
Asking for Preferences

Which aspect of multiple sclerosis do you want covered in depth?

This is a shared conversation. Sign in to Orris to start your own chat.